IP Library Granted Patent US 10,098,948
Granted Patent B2
US 10,098,948 · App. 15/018,346 · Granted Oct 16, 2018

Polysaccharide suitable to modulate immune response

Inventors: Ruud Albers (Rockanje, NL); Jari Helin (Helsinki, FI); Werner Klaffke (Vlaardingen, NL); Jean Hypolites Koek (Vlaardingen, NL); Petronella Anna Kreijveld (Vlaardingen, NL); Jari Natunen (Helsinki, FI); Erwin Werner Tareilus (Vlaardingen, NL); Richardus Paulus Anton Oranje (Vlaardingen, NL)
Assignee: NUTRILEADS B.V.
A61K39/39A23L29/30A61K31/715C08B37/0045C08B37/0048A23L5/00A23L7/00A23L33/125A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,948
App. No.
15/018,346
Granted
Oct 16, 2018
Kind
B2
Abstract

Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis , which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.

Claims (14)

1. A method of stimulating immune response in a mammal, comprising administering to a mammal in need of stimulation of its immune response a product selected from a food product, a beverage, a dietary food product, a clinical food product and a dietary supplement, the product comprising an aqueous carrot extract that is enriched in polysaccharides having

(i) a backbone comprising alternating rhamnogalacturonan-I cores and alpha(1,4)-linked polygalacturonic acid or alpha(1,4)-linked oligogalacturonic acid cores,

wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide ranges from 2.5:1 to 1:1,

wherein the rhamnogalacturonan-I core comprises one or more side chains substituted at the 4-OH position of the rhamnosyl residues and having a backbone of at least one or more alpha(1,5)-linked arabinosyl residues,

wherein the rhamnogalacturonan-I core comprises one or more side chains substituted at the 4-OH position of the rhamnosyl residues and having a backbone of at least one or more beta(1,4)-linked galactosyl residues,

wherein the molar ratio of arabinosyl residues to rhamnosyl residues is between 50:1 and 1:2, and

(ii) a molecular weight of at least 70 kDa,

wherein the composition comprises from 0.0001 to 25% by weight of the polysaccharide, which is administered at a daily dose of between 10 and 10,000 mg.

2. The method according to claim 1 , wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide ranges from 2:1 to 1:1.

3. The method according to claim 1 , wherein the polysaccharide has a molecular weight between 70 and 2,000 kDa.

4. The method according to claim 1 , wherein the polysaccharide is obtained from plants of the species Camellia sinensis, Malus domestica or Beta vulgaris L.

5. The method according to claim 1 for treating or increasing natural resistance of a subject against common cold.

6. The method according to claim 1 , wherein the polysaccharide is administered as an adjuvant for a vaccine.

7. The method according to claim 1 , wherein the composition is an edible product or pharmaceutical composition.

Priority Claims (1)
EP 09178876 · Dec 11, 2009 · regional
Continuity (2)
Division 13514937
Related Publication 20160151485A1 · Jun 2, 2016